Ismael Galve-Roperh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8856927/publications.pdf

Version: 2024-02-01

83 papers	8,330 citations	43973 48 h-index	66788 78 g-index
84 all docs	84 docs citations	84 times ranked	6378 citing authors

#	Article	IF	Citations
1	Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice. Cell Death and Disease, 2022, 13, .	2.7	6
2	Î”⁹â€‘Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo. Glia, 2021, 69, 532-545.	2.5	21
3	Identification of BiP as a CB₁ Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain. Journal of Neuroscience, 2021, 41, 7924-7941.	1.7	14
4	Î” 9 â€‘Tetrahydrocannabinol promotes functional remyelination in the mouse brain. British Journal of Pharmacology, 2021, 178, 4176-4192.	2.7	11
5	Cannabinoid-induced motor dysfunction <i>via</i> autophagy inhibition. Autophagy, 2020, 16, 2289-2291.	4.3	1
6	Endocannabinoid signalling in stem cells and cerebral organoids drives differentiation to deep layer projection neurons via CB1 receptors. Development (Cambridge), 2020, 147, .	1.2	9
7	Possible therapeutic applications of cannabis in the neuropsychopharmacology field. European Neuropsychopharmacology, 2020, 36, 217-234.	0.3	24
8	Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 2020, 45, 877-886.	2.8	51
9	Inhibition of striatonigral autophagy as a link between cannabinoid intoxication and impairment of motor coordination. ELife, 2020, 9, .	2.8	7
10	Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Translational Neurodegeneration, 2019, 8, 9.	3.6	24
11	Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons. Neuropharmacology, 2019, 150, 134-144.	2.0	15
12	Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors. Cerebral Cortex, 2018, 28, 307-322.	1.6	25
13	Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum. Neuropsychopharmacology, 2018, 43, 964-977.	2.8	52
14	Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders. Biochemical Pharmacology, 2018, 157, 85-96.	2.0	16
15	Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia. Frontiers in Pharmacology, 2018, 9, 1508.	1.6	8
16	Loss of Cannabinoid CB₁Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. Cerebral Cortex, 2017, 27, 5303-5317.	1.6	23
17	Cannabinoids as Regulators of Neural Development and Adult Neurogenesis. Pancreatic Islet Biology, 2017, , 117-136.	0.1	4
18	Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke. Stroke, 2017, 48, 204-212.	1.0	58

#	Article	IF	Citations
19	Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Frontiers in Pharmacology, 2017, 8, 269.	1.6	116
20	A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntingtonâ€™s disease. Journal of Neurology, 2016, 263, 1390-1400.	1.8	105
21	Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK. Journal of Neuroscience, 2016, 36, 10611-10624.	1.7	12
22	VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntingtonâ€™s disease. Scientific Reports, 2016, 6, 29789.	1.6	61
23	MicroRNA let-7d is a target of cannabinoid CB 1 receptor and controls cannabinoid signaling. Neuropharmacology, 2016, 108, 345-352.	2.0	23
24	The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death and Differentiation, 2015, 22, 1618-1629.	5.0	109
25	Î”-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. European Neuropsychopharmacology, 2015, 25, 958-965.	0.3	62
26	Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB ₁ receptors on developing cortical neurons. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13693-13698.	3.3	120
27	CB₁Cannabinoid Receptor-Dependent Activation of mTORC1/Pax6 Signaling Drives Tbr2 Expression and Basal Progenitor Expansion in the Developing Mouse Cortex. Cerebral Cortex, 2015, 25, 2395-2408.	1.6	30
28	A restricted population of CB ₁ cannabinoid receptors with neuroprotective activity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8257-8262.	3.3	136
29	Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in Lipid Research, 2013, 52, 633-650.	5.3	240
30	Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology, 2013, 71, 204-215.	2.0	26
31	The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. International Journal of Neuropsychopharmacology, 2013, 16, 1407-1419.	1.0	225
32	Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link?. Current Neuropharmacology, 2013, 11, 263-275.	1.4	20
33	Endocannabinoids via CB₁receptors act as neurogenic niche cues during cortical development. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3229-3241.	1.8	76
34	The CB₁Cannabinoid Receptor Drives Corticospinal Motor Neuron Differentiation through the Ctip2/Satb2 Transcriptional Regulation Axis. Journal of Neuroscience, 2012, 32, 16651-16665.	1.7	79
35	CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling. Journal of Biological Chemistry, 2012, 287, 1198-1209.	1.6	145
36	Cannabis, endocannabinoids and neurodevelopment. , 2011, , 66-81.		2

#	Article	IF	Citations
37	Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntingtonâ€™s disease. Brain, 2011, 134, 119-136.	3.7	178
38	The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 371-382.	1.8	94
39	Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain, 2009, 132, 3152-3164.	3.7	323
40	The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking. Journal of Biological Chemistry, 2008, 283, 13320-13329.	1.6	141
41	Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8760-8765.	3.3	263
42	Mechanisms of Control of Neuron Survival by the Endocannabinoid System. Current Pharmaceutical Design, 2008, 14, 2279-2288.	0.9	113
43	Targeting Cannabinoid Receptors in Brain Tumors. , 2008, , 361-374.		1
44	The CB1 Cannabinoid Receptor Mediates Excitotoxicity-induced Neural Progenitor Proliferation and Neurogenesis*. Journal of Biological Chemistry, 2007, 282, 23892-23898.	1.6	146
45	Cannabinoids Induce Glioma Stem-like Cell Differentiation and Inhibit Gliomagenesis. Journal of Biological Chemistry, 2007, 282, 6854-6862.	1.6	116
46	The emerging functions of endocannabinoid signaling during CNS development. Trends in Pharmacological Sciences, 2007, 28, 83-92.	4.0	357
47	The Endocannabinoid System and Neurogenesis in Health and Disease. Neuroscientist, 2007, 13, 109-114.	2.6	107
48	Cannabinoids and Gliomas. Molecular Neurobiology, 2007, 36, 60-67.	1.9	82
49	A pilot clinical study of Î”9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer, 2006, 95, 197-203.	2.9	287
50	R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB2 receptor. Biochemical Pharmacology, 2006, 72, 1697-1706.	2.0	53
51	Endocannabinoids: A New Family of Lipid Mediators Involved in the Regulation of Neural Cell Development. Current Pharmaceutical Design, 2006, 12, 2319-2325.	0.9	86
52	Nonâ€psychoactive CB 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB Journal, 2006, 20, 2405-2407.	0.2	201
53	The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells. Journal of Neuroscience, 2006, 26, 1551-1561.	1.7	225
54	The endocannabinoid system drives neural progenitor proliferation. FASEB Journal, 2005, 19, 1704-1706.	0.2	291

#	Article	IF	Citations
55	Cannabinoids and ceramide: Two lipids acting hand-by-hand. Life Sciences, 2005, 77, 1723-1731.	2.0	69
56	Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 2004, 47, 315-323.	2.0	70
57	Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. Journal of Cell Biology, 2002, 158, 1039-1049.	2.3	160
58	The Endocannabinoid Anandamide Inhibits Neuronal Progenitor Cell Differentiation through Attenuation of the Rap1/B-Raf/ERK Pathway. Journal of Biological Chemistry, 2002, 277, 46645-46650.	1.6	212
59	Direct Calcium Binding Results in Activation of Brain Serine Racemase. Journal of Biological Chemistry, 2002, 277, 27782-27792.	1.6	116
60	Mechanism of Extracellular Signal-Regulated Kinase Activation by the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2002, 62, 1385-1392.	1.0	173
61	Cannabinoids and cell fate. , 2002, 95, 175-184.		148
62	Evidence for the Lack of Involvement of Sphingomyelin Hydrolysis in the Tumor Necrosis Factor-Induced Secretion of Nerve Growth Factor in Primary Astrocyte Cultures. Journal of Neurochemistry, 2002, 71, 498-505.	2.1	10
63	Ceramide Signaling in Cannabinoid Action. Molecular Biology Intelligence Unit, 2002, , 125-132.	0.2	0
64	Ceramide: a new second messenger of cannabinoid action. Trends in Pharmacological Sciences, 2001, 22, 19-22.	4.0	115
65	The CB₁ Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan. Molecular Pharmacology, 2001, 59, 955-959.	1.0	98
66	Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine, 2001, 78, 613-625.	1.7	207
67	The Stimulation of Ketogenesis by Cannabinoids in Cultured Astrocytes Defines Carnitine Palmitoyltransferase I as a New Ceramide-Activated Enzyme. Journal of Neurochemistry, 2001, 72, 1759-1768.	2.1	72
68	Signaling at zero g: a comment. Trends in Biochemical Sciences, 2001, 26, 533.	3.7	1
69	Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 2000, 6, 313-319.	15.2	610
70	The CB₁Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase. Molecular Pharmacology, 2000, 58, 814-820.	1.0	186
71	Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1-phosphate and induces cell death. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7859-7864.	3.3	192
72	De novoâ€synthesized ceramide signals apoptosis in astrocytes via extracellular signalâ€regulated kinase. FASEB Journal, 2000, 14, 2315-2322.	0.2	144

#	Article	IF	Citations
73	Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters, 1999, 463, 235-240.	1.3	145
74	Î”9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Letters, 1998, 436, 6-10.	1.3	248
75	Involvement of Sphingomyelin Hydrolysis and the Mitogen-Activated Protein Kinase Cascade in the Î”⁹-Tetrahydrocannabinol-Induced Stimulation of Glucose Metabolism in Primary Astrocytes. Molecular Pharmacology, 1998, 54, 834-843.	1.0	189
76	cAMP signalling mechanisms with aging in the Ceratitis capitata brain. Mechanisms of Ageing and Development, 1997, 97, 45-53.	2.2	13
77	Ceramide-induced translocation of protein kinase C Î¶ in primary cultures of astrocytes. FEBS Letters, 1997, 415, 271-274.	1.3	36
78	Induction of nerve growth factor synthesis by sphingomyelinase and ceramide in primary astrocyte cultures. Molecular Brain Research, 1997, 52, 90-97.	2.5	35
79	Adaptations of the Î²-adrenoceptor-adenylyl cyclase system in rat skeletal muscle to endurance physical training. Pflugers Archiv European Journal of Physiology, 1997, 434, 809-814.	1.3	13
80	Regulation of nerve growth factor secretion and mRNA expression by bacterial lipopolysaccharide in primary cultures of rat astrocytes. , 1997, 49, 569-575.		23
81	Levels and activity of brain protein kinase C Î± and Î¶ during the aging of the medfly. Mechanisms of Ageing and Development, 1996, 92, 21-29.	2.2	5
82	Addition of phosphatidylcholine-phospholipase C induces cellular redistribution and phosphorylation of protein kinase C Î¾ in C 6 glial cells. Neuroscience Letters, 1996, 219, 68-70.	1.0	5
83	Phosphatidylcholine-phospholipase C mediates the induction of nerve growth factor in cultured glial cells. FEBS Letters, 1995, 364, 301-304.	1.3	15